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SUMMARY 
 
International Circumpolar Surveillance (ICS), a population-based surveillance system for 
invasive bacterial diseases, has been established in the U.S. Arctic, Northern Canada, Greenland, 
Iceland, Norway, and Finland.  Data collection began in 1999 and includes the organisms 
Streptococcus pneumoniae (Sp), Haemophilus influenzae (Hi), Neisseria meningitidis (Nm), and 
groups A and B streptococcus (GAS, GBS).  This report reviews the data collected for the year 
2002. 
 
Data on invasive disease with the organism Streptococcus pneumoniae are collected from all 
participating countries; data on invasive disease due to the remaining organisms are currently 
collected by the U.S. Arctic, Northern Canada, and, beginning with this reporting year, 
Greenland.  A total of 1,698 cases of invasive pneumococcal disease were identified in 2002.  
Overall, rates of invasive S. pneumoniae were highest in individuals less than 2 years of age, 
however, the median age of cases was greater than 40 years in all countries except N. Canada.  
Case fatality ratios ranged from 4-29%.  Race and ethnicity data are collected only in N. Canada 
and the U.S. Arctic; rates of invasive pneumococcal disease in Northern Canadian Aboriginals 
and U.S. Arctic Native populations were 60 and 25 cases per 100,000 population, respectively, 
which represents an increase in disease from 2000 in Northern Canadian Aboriginals and a 
decrease in disease in U.S. Arctic Natives.  Pneumonia and septicemia were the most common 
clinical presentations; cigarette smoking was the most common risk factor.  Pneumococcal 
vaccine status was reported from four countries:  Canada, Greenland, Norway, and the U.S. 
Arctic and ranged from 0-36% of reported cases vaccinated.  The most common S. pneumoniae 
serotypes in Finland and the U.S. Arctic are 4 and 14; in Iceland the most common serotype is 7; 
and in Greenland and N. Canada the most common serotype is 1. 
 
Data on invasive disease due to Haemophilus influenzae, Neisseria meningitidis, and groups A 
and B streptococcus are currently collected in Greenland, Northern Canada, and the U.S. Arctic.  
A total of 19 H. influenzae cases, 9 N. meningitidis cases, 47 group A streptococcus cases, and 
25 group B streptococcus cases were reported in 2002.  In general, the highest rates of disease as 
a result of all organisms occurred in N. Canada Aboriginal or Alaska Native persons less than 
two years of age; however in N. Canada the highest rates of meningococcal disease occurred in 
non-Aboriginals and in the U.S. Arctic the highest rates of invasive disease with Haemophilus 
influenzae occurred in the 65+ years of age category. 
 
Surveillance Organisms Reported by Country, ICS 2002 Data 
 
Country 
S. pneumoniae 
n (rate*) 
H. influenzae 
n (rate*) 
N. meningitidis 
n (rate*) 
group A strep 
n (rate*) 
group B strep 
n (rate*) 
Finland 599 (12) N/A N/A N/A N/A 
Greenland 16 (28) 0 (0) 2 (4) 0 (0) 0 (0) 
Iceland 45 (16) N/A N/A N/A N/A 
N. Canada 35 (27) 8 (6) 1 (1) 5 (4) 2 (2) 
Norway 914 (20) N/A N/A N/A N/A 
U.S. Arctic 89 (14) 11 (2) 6 (1) 42 (7) 23 (4) 
Total 1698 (16) 19 (2) 9 (1) 47 (6) 25 (3) 
*Cases per 100,000 
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INTRODUCTION 
 
In January, 1999, the United States and Canada began international cooperative population-based 
surveillance for invasive Streptococcus pneumoniae by all laboratories serving residents of the 
North American Arctic.  In January, 2000, this surveillance system expanded to include invasive 
diseases with the following organisms:  Haemophilus influenzae (all types), Neisseria 
meningitidis, group A streptococcus, and group B streptococcus.  These pathogens were selected 
for ICS because rates of these diseases are elevated in indigenous peoples of the north, strains 
demonstrate resistance to commonly used antibiotics, they are routinely cultured in clinical 
laboratories, and clinically important serotypes of Streptococcus pneumoniae, Haemophilus 
influenzae, and Neisseria meningitidis are vaccine preventable in infants and adults. 
 
Denmark’s autonomous region of Greenland joined ICS in 2000, and Iceland, Norway (including 
Svalbard), and Finland joined in 2001.  To date, year 2002 data has been submitted by Finland, 
Greenland, Iceland, Northern Canada, Norway, and the U.S. Arctic (Alaska).  This report 
contains year 2002 data on all five surveillance organisms from Greenland, Northern Canada, 
and the U.S. Arctic, and Streptococcus pneumoniae data from Finland, Iceland, and Norway. 
 
GOALS 
 
The goal of ICS is to establish an integrated network of hospital and public health facilities 
throughout the Arctic countries to monitor infectious diseases of concern.  Linking public health 
facilities within Arctic nations will allow for the collection and sharing of uniform laboratory and 
epidemiological data that will describe the prevalence of infectious diseases in Arctic 
populations and assist in the formulation of prevention and control strategies. 
 
The project, initiated in 1998, focused on establishing an ICS system for diseases caused by 
Streptococcus pneumoniae.  This bacterium causes pneumonia, meningitis, and bacteremia in 
both the very young and the elderly.  Once easily treated with antibiotics, this bacterium is now 
becoming resistant to commonly used antibiotics.  This is of great concern to the public health 
community and is increasingly a target for surveillance by many countries worldwide.  A 
polysaccharide vaccine is available for use in persons two years of age and older.  In the U.S. 
Arctic, this vaccine is recommended for all those 55 years of age and older.  A conjugate vaccine 
for infants has been developed and is licensed for use in the U.S., Canada, and the European 
Union.  The fact that diseases caused by Streptococcus pneumoniae are already being monitored 
by many public health authorities within the Arctic states makes establishing a circumpolar 
surveillance system for this infection feasible.  In addition, due to the availability of 
polysaccharide and conjugate vaccines, much of the morbidity and mortality caused by 
Streptococcus pneumoniae is currently preventable. 
 
ICS objectives include: 
 
• Identify key public health contacts within Arctic countries.  These persons should be familiar 
with infectious disease surveillance systems in place (particularly surveillance systems for 
diseases caused by Streptococcus pneumoniae) in the member country.  Through 
correspondence and working group meetings, the scope and gaps of the surveillance systems 
are determined. 
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• Determine the comparability of laboratory and data collection methods, and negotiate 
standard protocols and quality control programs. 
 
• Share and report data in agreed upon formats. 
 
• Form a working group of key laboratory and public health contacts to coordinate 
pneumococcal surveillance within their respective jurisdictions.  This group meets on a 
regular basis to review problems, progress, compliance, report generation, and future plans. 
 
• Form a steering committee of national Arctic health experts to coordinate new objectives and 
initiatives within ICS. 
 
This program forms a framework through which surveillance of other infectious diseases as well 
as prevention and control programs can be added.  Other infectious diseases of circumpolar 
community concern include:  other invasive bacterial diseases (caused by Haemophilus 
influenzae, Neisseria meningitidis, groups A and B streptococcus), tuberculosis, HIV, hepatitis, 
foodborne diseases (botulism, brucellosis), waterborne diseases, respiratory diseases of children 
such as those caused by respiratory syncytial virus, and chronic conditions related to infectious 
agents (hepatitis B virus and liver cancer, human papilloma virus and cervical cancer).  In 
addition, the surveillance model developed by this program for infectious disease may be 
adapted to monitor other non-infectious human health priorities of community concern. 
 
METHODS 
 
ICS is coordinated by personnel at the Arctic Investigations Program, Centers for Disease 
Control and Prevention, in Anchorage, Alaska. 
 
A case of invasive Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, 
or groups A and B streptococcus is defined as an isolate of the bacteria from a normally sterile 
site, including blood, cerebrospinal fluid, pleural fluid, peritoneal fluid or joint fluid that has 
been taken from a resident of the surveillance area. 
 
In the U.S. Arctic and Northern Canada, laboratory, demographic and clinical data are collected 
continually by ICS, while in Greenland, Iceland, Norway, and Finland, summary data are 
submitted to ICS in aggregate at the end of the year. 
 
Quality Control 
 
Currently 37 clinical laboratories in the U.S. Arctic and N. Canada forward isolates from patients 
with invasive pneumococcal disease to reference laboratories in Alaska and Canada respectively.  
To ensure inter-laboratory comparability of Streptococcus pneumoniae serotyping and 
antimicrobial susceptibility testing between two reference laboratories in Canada (Alberta and 
Quebec) and one in the U.S. (Alaska), the ICS Streptococcus pneumoniae inter-laboratory 
quality control (QC) program was established in 1999. 
 
Each reference laboratory is responsible for exporting one QC panel of seven Streptococcus 
pneumoniae isolates each year to each of the other laboratories using a transportation medium of 
their choice for a total of 21 Strep pneumoniae isolates per year.  Serotyping was performed by 
Quellung reaction.  Minimum inhibitory concentration (MIC) is determined for each QC isolate 
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and for ATCC strain 49619 for those antibiotics which are routinely tested in each laboratory.  
MIC results for each laboratory are expected to be within one log2 dilution of each other 
regardless of testing method.  Discrepancies of results are documented and examined to 
determine causes and solutions. 
 
Finland 
 
• 23 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Finland. 
o All invasive isolates of Sp submitted to the National Public Health Institute (KTL) 
laboratory in Oulu. 
 
• Antimicrobial susceptibility testing of Sp isolates was performed by agar dilution method at 
district hospital laboratories as well as the KTL laboratory. 
 
• Serotyping is performed at the KTL laboratory by counter-immune-electrophoresis. 
 
• Population estimates for 2002 were obtained from the website http://www.stat.fi 
 
Greenland 
 
• 15 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Greenland. 
o All invasive isolates of Sp, Hi, Nm, GAS, and GBS submitted to reference laboratories in 
Nuuk and Copenhagen. 
 
• Antimicrobial susceptibility testing of Sp isolates was performed by agar dilution at the 
central laboratory at Queen Ingrid’s Hospital in Nuuk. 
 
• Serotyping was performed at the Statens Serum Institute in Copenhagen, Denmark, by the 
Quellung method. 
 
• Clinical and demographic data for every case of invasive Sp, Hi, Nm, GAS, and GBS was 
collected by public health authorities at the end of the year and entered onto a standardized 
collection tool, the Bacterial Diseases Surveillance Form (BDSF), which is also used in 
Iceland, Northern Canada, and the U.S. Arctic. 
 
• Population estimates for 2002 were obtained from the website http://www.statgreen.gl 
 
Iceland 
 
• 10 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Iceland. 
o All invasive isolates of Sp submitted to the reference hospital in Reykjavik. 
 
• Antimicrobial susceptibility testing of Sp isolates is performed by disc diffusion method at 
the Landspitali University Hospital (LUH) in Reykjavik and the laboratory at the regional 
hospital in Akureyri.  All oxacillin resistant isolates are then analyzed by E test. 
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• Serotyping is performed at the LUH by coagglutination using antisera from Statens Serum 
Institute. 
 
• Clinical and demographic data for every case of invasive Sp was collected by public health 
authorities at the end of the year and entered onto the same collection form (BDSF) used in 
Greenland, Northern Canada, and the U.S. Arctic. 
 
• Population estimates for 2002 were obtained form the website http://www.hagstofa.is 
 
Northern Canada 
 
• 14 Canadian laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of the Yukon Territory, 
Northwest Territories, Nunavut, Northern Quebec, and Northern Laborador. 
o Submit all invasive isolates of Sp, Hi, Nm, GAS, and GBS to one of two reference 
laboratories in Canada. 
o Sp, Hi, GAS, and GBS isolates are serotyped by the Quellung method using Statens 
Serum Institute antisera. 
 
• Antimicrobial susceptibility of Sp, GAS, and GBS isolates was tested by micro-broth dilution 
(according to NCCLS recommendations). 
 
• Communicable disease consultants located within one of the five regions of Northern Canada 
provided clinical and demographic information on the same collection form (BDSF) used in 
Greenland, Iceland, and the U.S. Arctic. 
 
• Laboratory and clinical data are forwarded to the ICS coordinator at AIP in Anchorage. 
 
• Population estimates for 2002 were obtained from the website http://www.statcan.ca 
 
Norway 
 
• 33 district hospital laboratories participate in ICS. 
o Provide diagnostic microbiology services for all residents of Norway. 
o All invasive isolates of Sp submitted to one of two reference laboratories in Oslo or 
Tromso. 
 
• Antimicrobial susceptibility testing of Sp isolates is performed using the disc diffusion 
method at district hospital laboratories, the reference laboratory in Tromso or the main 
national laboratory in Oslo. 
 
• Serotyping is performed at the Statens Serum Institute in Denmark by the Quellung method. 
 
• Population estimates for 2002 were obtained from the website http://www.ssb.no 
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U.S. Arctic 
 
• Population-based surveillance in the state of Alaska 
o Since 1980 for invasive Hi. 
o Since 1986 for invasive Sp. 
o Since 1999 for invasive diseases caused by Nm, GAS, and GBS. 
o Coordinated by the Arctic Investigations Program (AIP), National Center for Infectious 
Disease, Centers for Disease Control and Prevention, in Anchorage, Alaska. 
 
• 23 laboratories providing diagnostic services to residents of Alaska submitted to AIP isolates 
of Sp, Hi, Nm, GAS, and GBS cultured in blood, cerebrospinal fluid, or from other sterile 
sites. 
o Sp and Hi isolates are sertoyped by the Quellung method using Statens Serum Institute 
antisera. 
o Serogroup testing of Nm isolates from Alaska is performed at the Canadian National 
Centre for Meningococcal Disease in the CNS Infections Laboratory in Winnipeg. 
♦ By the slide agglutination method using specific antisera. 
♦ By PCR detection of the siaDgene responsible for synthesis of the serogroup-specific 
polysialytransferase. 
 
• Antimicrobial susceptibility testing of Sp isolates is performed at AIP by micro-broth 
dilution (according to NCCLS recommendations). 
 
• Clinical and demographic information on each case-patient is recorded by AIP research 
nurses onto the same collection form (BDSF) used in Greenland, Iceland, and Northern 
Canada. 
 
• Population estimates for 2002 were obtained from the website http://www.labor.state.ak.us 
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RESULTS 
 
Streptococcus pneumoniae 
 
Case Demographics
 
A total of 1,698 cases of invasive disease caused by Streptococcus pneumoniae were reported to 
ICS during 2002 by Finland, Greenland, Iceland, N. Canada, Norway, and the U.S. Arctic.  The 
highest rates of disease (28 per 100,000) occurred in Greenland and the lowest in Finland (12 per 
100,000) with an overall rate for the ICS circumpolar region of 16 per 100,000; 54% of all cases 
occurred in males.  The median age of cases overall was 57 years with the lowest median age in 
N. Canada (27 years) and the highest in Norway (63 years).  Case fatality ratios ranged from 7% 
in Norway to 19% in Greenland; the overall case fatality ratio was 8%. 
 
Streptococcus pneumoniae Case Demographics, ICS 2002 Data 
Country Population 
# 
Cases Rate* 
Sex  
M (%) 
Median Age 
(range) yrs 
Deaths 
n (CFR†) 
Finland 5,208,839 599 12 336 (56) 53 (0 – 95) Unknown‡ 
Greenland 56,542 16 28 8 (50) 44 (0.5 – 61) 3 (19) 
Iceland 287,559 45 16 31 (69) 47 (0.4 – 96) 7 (16) 
N. Canada 127,721 35 27 19 (54) 27 (0.5 – 79) 3 (10)a
Norway 4,551,996 914 20 466 (51) 63 (0.1 – 97) 67 (7)a
U.S. Arctic 643,786 89 14 59 (66) 45 (0.2 – 94) 11 (12) 
Total 10,876,443 1,698 16 919 (54) 57 (0 – 97) 91 (8) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Case outcomes not reported from Finland 
aCase outcomes unknown in cases from N. Canada (5), Norway (1) 
 
Streptococcus pneumoniae by Age Category, ICS 2002 Data 
Age  Finland Greenland Iceland N. Canada Norway U.S. Arctic
Population 115,025 1,696 8,327 4,736 119,276 20,625 
Cases (%) 51 (8) 3 (19) 8 (18) 6 (17) 53 (6) 14 (16) <2 yrs 
Rate* 44 177 96 127 44 68 
Population 1,149,165 17,310 78,389 43,822 1,062,478 194,454 
Cases (%) 57 (10) 2 (12) 4 (9) 10 (29) 44 (5) 13 (15) 2-19 yrs 
Rate* 5 12 5 23 4 7 
Population 3,155,166 34,561 167,367 73,764 2,690,249 390,104 
Cases (%) 307 (51) 11 (69) 16 (35) 15 (43) 386 (42) 47 (53) 20-64 yrs 
Rate* 10 32 10 20 14 12 
Population 789,483 2,975 33,476 5,399 679,993 38,603 
Cases (%) 184 (31) 0 (0) 17 (38) 4 (11) 431 (47) 15 (17) 65+ yrs 
Rate* 23 0 51 74 63 39 
Population 5,208,839 56,542 287,559 127,721 4,551,996 643,786 
Cases 599 16 45 35 914 89 All ages 
Rate* 12 28 16 27 20 14 
*Number of cases per 100,000 per year 
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When stratified by age, the highest rates of disease in each age category were in Greenland and 
N. Canada; however, the total number of cases reported in Greenland was small and therefore 
rates are unstable and should be regarded only as an indication of relative differences.  The 
lowest rates were in Finland.  The highest rates of disease in all countries occurred in those cases 
less than two years of age and in cases 65+ years of age, with the exception of Greenland, where 
no cases were reported in individuals 65+ years of age. 
 
Seasonality
 
Streptococcus pneumoniae was diagnosed in each country throughout the year in 2002.  With the 
exception of Greenland, the highest proportion of S. pneumoniae cases were diagnosed during 
the fourth quarter (October, November, December) of the calendar year.  The Greenland data 
showed no distinct seasonality although the number of cases reported was small. 
 
Race
 
Race and ethnicity data was collected in N. Canada and the U.S. Arctic.  Rates of invasive 
pneumococcal disease were consistently higher in Aboriginal and Native populations than in 
non-Aboriginal and non-Native populations.  The highest rates of disease occurred in Aboriginal 
and Native populations less than 2 years of age in both countries.   
 
Streptococcus pneumoniae by Race and Age Categories, ICS 2002 Data 
N. Canada* U.S. Arctic† Age 
(yrs) 
 
Aboriginal Non-Aboriginal Native Non-Native 
Population 3,593 1,143 5,356 15,269 <2 Cases (rate‡) 5 (139) 1 (87) 7 (131) 5 (33) 
Population 31,801 12,021 49,057 145,397 2-19 Cases (rate‡) 10 (31) 0 (0) 5 (10) 7 (5) 
Population 37,331 36,433 63,373 326,731 20-64 Cases (rate‡) 7 (19) 4 (11) 28 (44) 17 (5) 
Population 3,032 2,367 7,017 31,586 65+ Cases (rate‡) 3 (99) 1 (42) 3 (43) 10 (32) 
Population 75,757 51,964 124,803 518,983 All 
Ages Cases (rate‡) 25 (33) 6 (12) 43 (34) 39 (8) 
*Race unknown in 4 cases 20-64 years 
†Race unknown in 2 cases <2 years, 1 case 2-19 years, 2 cases 20-64 years, 2 cases 65+ years 
‡Number of cases per 100,000 per year 
 
Clinical Presentation
 
The most common clinical presentations associated with Streptococcus pneumoniae were 
pneumonia, bacteremia or septicemia, and meningitis.  Clinical diagnoses other than bacteremia 
and meningitis are not reported in the Finland and Iceland S. pneumoniae data.  In Greenland, the 
clinical presentation reported most often was septicemia (44%); and in N. Canada, Norway, and 
the U.S. Arctic, it was pneumonia (71%, 43% and 62% respectively). 
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Clinical Presentation of Reported Streptococcus pneumoniae Cases, ICS 2002 Data 
Finland Greenland Iceland  
n (%) n (%) n (%) 
N Canada
n (%) 
Norway 
n (%) 
US Arctic 
n (%) 
Pneumonia* 0 (0) 4 (25) 0 (0) 25 (71) 390 (43) 55 (62) 
Septicemia 0 (0) 7 (44) 0 (0) 3 (9) 292 (32) 18 (20) 
Bacteremia 580 (97) 0 (0) 44 (98) 2 (6) 113 (12) 3 (3) 
Meningitis 19 (3) 4 (25) 1 (2) 2 (6) 68 (7) 5 (6) 
Empyema 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 6 (7) 
Cellulitis* 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 0 (0) 
Septic arthritis 0 (0) 0 (0) 0 (0) 0 (0) 4 (<1) 0 (0) 
Endocarditis 0 (0) 1 (6) 0 (0) 0 (0) 0 (0) 0 (0) 
Peritonitis 0 (0) 0 (0) 0 (0) 2 (6) 0 (0) 0 (0) 
Epiglottitis 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 
Amnionitis 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 
Other 0 (0) 0 (0) 0 (0) 0 (0) 43 (5) 2 (2) 
Unknown 0 (0) 0 (0) 0 (0) 0 (0) 2 (<1) 0 (0) 
Total Cases 599 16 45 35 914 89 
*with bacteremia 
 
Risk Factors
 
The most frequently reported medical conditions or risk factors associated with Streptococcus 
pneumoniae in adults 18 years and older were cigarette smoking and alcohol abuse.  Cigarette 
smoking was reported in 47% of adult cases in N. Canada and 34% of adult cases in the U.S. 
Arctic.  Alcohol abuse was reported in 47% of adult cases in N. Canada and 46% of adult cases 
in the U.S. Arctic; Greenland did not report risk factors in any cases. 
 
Streptococcus pneumoniae Risk Factor/Medical Conditions in Adults*, ICS 2002 Data 
 N. Canada U.S. Arctic 
n (%) n (%) 
Cigarette Smoking 9 (47) 30 (48) 
Chronic Lung Disease and/or Asthma 3 (16) 19 (30) 
Alcohol Abuse 9 (47) 29 (46) 
Immunosuppressive Therapy 2 (11) 3 (5) 
Diabetes 4 (21) 6 (10) 
Asplenia 1 (5) 6 (10) 
Total Adult* Cases 19 63 
*≥ 18 years 
 
Vaccination Status
 
In Finland, Iceland, N. Canada, Norway, and the U.S. Arctic, 23-valent pneumococcal 
polysaccharide vaccine (PS23) is recommended for persons 55 years and older (U.S. Arctic), 
over 60 years (Iceland) or over 65 years of age (Finland, N. Canada, Norway), and to persons 
greater than two years of age (Finland, Iceland, Norway, U.S. Arctic) or greater than five years 
of age (N. Canada) with specific medical problems.  The pneumococcal 7-valent conjugate 
vaccine (PCV7) was introduced into the infant immunization schedule in the U.S. Arctic in 
January, 2001.  Vaccine data was not reported from Finland and Iceland.  Seventeen and 
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seventy-nine percent of Streptococcus pneumoniae cases in children less than 2 years of age with 
known vaccination status were vaccinated with PCV7 in N. Canada and the U.S. Arctic, 
respectively.  Only 3% of Streptococcus pneumoniae cases with known vaccination status in 
Norway were vaccinated with PCV7 indicating less frequent use of this vaccine.  A similar 
pattern in Norway of vaccine use in adults eligible for PS23 vaccine is apparent.  In N. Canada 
and the U.S. Arctic, higher percentages of adults eligible for PS23 vaccine are vaccinated. 
 
Streptococcus pneumoniae Case Vaccination Status for Pneumococcal Vaccine, ICS 2002 Data 
N. 
Canada 
U.S. 
Arctic 
 
Norway 
Total cases eligible for PCV7 vaccine* 6 53 14 
Vaccine status known in cases eligible for PCV7 6 37 14 
Cases eligible for PCV7 vaccinated (%)† 1 (17) 1 (3) 11 (79) 
Total cases eligible for PS23 vaccine‡ 4 431 28 
Vaccine status known in cases eligible for PS23 4 176 12 
Cases eligible for PS23 vaccinated (%)† 3 (75) 8 (5) 7 (58) 
*Children less than 2 years of age 
†Percent of vaccine status known cases 
‡Adults 55 years and older in the U.S. Arctic, 65 years and older in N. Canada and Norway 
 
Serotypes 
 
The most prevalent Streptococcus pneumoniae serotypes reported by ICS countries in 2002 were 
4, 6B, 9V and 14, all of which are included in both the 7-valent conjugate vaccine and the 23-
valent pneumococcal polysaccharide vaccine.  Serotypes were not reported by Norway.  In the 
following table, yellow highlights the top three most common serotypes in each country.  In N. 
Canada serotypes 14 and 23F were equally ranked third.  
 
 Streptococcus pneumoniae Serotypes by Country, ICS 2002 Data 
Finland Greenland Iceland 
Serotype n (%) n (%) n (%) 
N. Canada 
n (%) 
U.S. Arctic 
n (%) 
1 5 (1) 2 (13) 1 (2) 9 (29) 0 (0) 
3 46 (8) 2 (13) 4 (9) 0 (0) 4 (5) 
4 83 (14) 1 (7) 0 (0) 0 (0) 12 (16) 
5/10F 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
6A 24 (4) 1 (7) 0 (0) 0 (0) 3 (4) 
6B 35 (6) 1 (7) 4 (9) 3 (10) 3 (4) 
7 0 (0) 0 (0) 14 (32) 0 (0) 0 (0) 
7F 32 (5) 0 (0) 0 (0) 0 (0) 6 (8) 
8 8 (1) 1 (7) 0 (0) 6 (19) 5 (7) 
9 0 (0) 0 (0) 3 (7) 0 (0) 0 (0) 
9N 20 (3) 0 (0) 0 (0) 0 (0) 7 (9) 
9V   45 (7) 1 (7) 0 (0) 1 (3) 0 (0) 
10 5 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
10A 0 (0) 0 (0) 0 (0) 0 (0) 2 (3) 
11 0 (0) 0 (0) 3 (7) 0 (0) 0 (0) 
11A 12 (2) 0 (0) 0 (0) 0 (0) 0 (0) 
12F 25 (4) 2 (13) 0 (0) 0 (0) 3 (4) 
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Finland Greenland Iceland 
n (%) 
N. Canada 
n (%) 
U.S. Arctic 
n (%) Serotype n (%) n (%) 
13 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
14 81 (13) 1 (7) 5 (11) 4 (13) 5 (7) 
15 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 
15A 3 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
15B 4 (1) 0 (0) 0 (0) 0 (0) 1 (1) 
15C 2 (<1) 1 (7) 0 (0) 0 (0) 2 (3) 
16 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
16F 0 (0) 0 (0) 0 (0) 0 (0) 4 (5) 
17 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
18 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 
18B 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
18C 29 (5) 0 (0) 0 (0) 0 (0) 0 (0) 
19 0 (0) 0 (0) 2 (5) 0 (0) 0 (0) 
19A 24 (4) 0 (0) 0 (0) 2 (6) 3 (4) 
19F 23 (4) 0 (0) 0 (0) 1 (3) 2 (3) 
20 6 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
22 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 
22A 0 (0) 0 (0) 0 (0) 0 (0) 3 (4) 
22F 21 (3) 1 (7) 0 (0) 0 (0) 4 (5) 
23 0 (0) 0 (0) 5 (11) 0 (0) 0 (0) 
23A 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
23F 35 (6) 0 (0) 0 (0) 4 (13) 1 (1) 
31 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
33 7 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
33F 0 (0) 1 (7) 0 (0) 0 (0) 2 (3) 
34 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 
35B 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
35F 9 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
38 3 (<1) 0 (0) 0 (0) 0 (0) 3 (4) 
39 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
 
Vaccine-Preventable Cases and Deaths
 
For the countries reporting serotype data, more than 87% of Streptococcus pneumoniae cases in 
persons ≥ 2 years of age were preventable with use of the 23-valent polysaccharide vaccine.  Use 
of the 7-valent conjugate vaccine would have potentially prevented 8-67% of Strep pneumoniae 
cases in children < 2 years of age in 2002.  The proportion of deaths potentially preventable with 
use of the 23-valent polysaccharide vaccine related to Streptococcus pneumoniae ranged from 
33% to 73%. 
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Proportion of Vaccine Preventable Cases/Deaths from Invasive Pneumococcal Disease, ICS 2002 Data 
Finland Greenland 
n/Denom* n/Denom* 
(%) (%) 
Iceland 
n/Denom* 
(%) 
N. Canada
n/Denom* 
(%) 
U.S. Arctic
n/Denom* 
(%) 
Cases ≥ 2 years old with serotype in the 
23-valent pneumococcal polysaccharide 
vaccine 
500/568 
(88) 
11/12 
(92) 
11/12 
(92) 
24/25 
(96) 
55/63 
(87) 
Cases < 2 years old with serotype in the 
7-valent pneumococcal conjugate 
vaccine 
22/35 
(63) 
1/3 
(33) 
3/5 
(60) 
4/6 
(67) 
1/13 
(8) 
Deaths (all ages) for which the serotype 
was contained in the 23-valent 
pneumococcal vaccine 
 
† 
 
2 (67‡) 
 
0 
 
1 (33‡) 
 
8 (73‡) 
*Number of isolates serotyped by country by age group 
†No outcome data reported by Finland 
‡Percentage of total deaths 
 
Outcome
 
A total of 91 deaths associated with Streptococcus pneumoniae were reported to ICS in 2002.  
Overall, the highest case fatality ratio (CFR) occurred in persons 65+ years of age (13%).  
Finland did not report outcome data. 
 
Streptococcus pneumoniae Age-Specific Case-Fatality Ratios (CFR), ICS 2002 Data 
<2 years 2-19 years 20-64 years 65+ years   All Ages 
# Cases 3 2 11 0 16 Greenland Deaths (CFR) 0 (0) 0 (0) 3 (27) 0 (0) 3 (19) 
# Cases 8 4 16 17 45 Iceland Deaths (CFR) 0 (0) 0 (0) 3 (19) 4 (23) 7 (16) 
# Cases 6* 10 15* 4 35* N. Canada Deaths (CFR) 0 (0) 0 (0) 2 (18) 1 (25) 3 (10) 
# Cases 53 44 386* 431 914* Norway Deaths (CFR) 2 (4) 1 (2)  14 (4) 50 (12) 67 (7) 
# Cases 14 13 47 15 89 U.S. Arctic Deaths (CFR) 0 (0) 1 (8) 6 (13) 4 (27) 11 (12) 
# Cases 84* 73 475* 467 1099* Total Deaths (CFR) 2 (2) 2 (3) 28 (6)  59 (13) 91 (8) 
*Outcome unknown in (1) N. Canada case < 2 years, (4) N. Canada and (1) Norway cases 20-64 years 
 
Antimicrobial Susceptibility
 
Streptococcus pneumoniae Penicillin Susceptibility Results, ICS 2002 Data 
 # Tested S* I* I* Serotypes R* R* Serotypes 
Finland 599 568 27 † 4 † 
Greenland 9 9 0  0  
Iceland 44 42 1 9 1 6B 
N. Canada 31 30 1 9V 0  
U.S. Arctic 76 67 7 6A (2), 6B (2), 14 (1), 19A (2) 2 14 (1), 19F (1) 
*S=Sensitive, I=Intermediate resistance, R=Fully resistant 
†Finnish serotype data is not linked to antimicrobial susceptibility data 
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In 2002, antimicrobial susceptibility results were reported to ICS from Finland, Greenland, 
Iceland, N. Canada, and the U.S. Arctic.  Of those isolates tested from the U.S. Arctic, 2% were 
fully resistant to penicillin, 9% had intermediate resistance.  The fully resistant isolates were 
serotypes 14 (50%) and 19F (50%).  The isolates that showed intermediate resistance were 
serotypes 6A (29%), 6B (29%), 14 (14%), and 19A (29%).  Finland submitted results from 599 
isolates; 1% were fully resistant to penicillin and 5% had intermediate resistance.  The Finnish 
serotype data is not linked to the antimicrobial susceptibility data, so no comparisons can be 
made.  In Iceland, 2% of isolates tested had intermediate and full resistance to penicillin and 
consisted of one each serotype 9 and 6B, respectively.   
 
Full resistance to trimethoprimsulfamethoxizole (TMP-Sulfa) was found in 17% of tested 
isolates from the U.S. Arctic, 6% from N. Canada, and 9% from Iceland.  The isolates that were 
fully resistant in the U.S. Arctic were serotypes 6A (23%), 19A (23%), 6B (15%), 33F (15%), 14 
(8%), 19F (8%), and 23F (8%).  In N. Canada, both fully resistant isolates were serotype 23F.  
Isolates from Iceland that were fully resistant to TMP-Sulfa were serotypes 9 (50%), 6B (25%), 
and 23 (25%).  Intermediate resistance to TMP-Sulfa was found in 3% of tested isolates from the 
U.S. Arctic (one each serotype 14 and 19F) and 5% from Iceland (one each serotype 6B and 9).   
 
Streptococcus pneumoniae TMP-Sulfa Susceptibility Results, ICS 2002 Data 
# 
Tested  S* I* I* Serotypes R* R* Serotypes 
Iceland 43 37 2 6B (1), 9 (1) 4 6B (1), 9 (1), 23 (2) 
N. Canada 31 28 1 6B 2 23F (2) 
U.S. Arctic 76 61 2 14 (1), 19F (1) 13 6A (3), 6B (2), 14 (1), 19A (3), 19F (1), 23F (1), 33F (2) 
*S=Sensitive, I=Intermediate resistance, R=Fully resistant 
 
In the U.S. Arctic, 9% of tested isolates were fully resistant to erythromycin and 4% from 
Iceland.  The serotypes found in the fully resistant isolates from the U.S. Arctic were 6B (29%), 
14 (29%), 6A (14%), 9N (14%), and 19F (14%).  In Iceland, the isolates that were fully resistant 
to erythromycin were serotypes 14 (50%) and 6B (50%). 
 
Streptococcus pneumoniae Erythromycin Susceptibility Results, ICS 2002 Data 
# 
Tested  S* I* I* Serotypes R* R* Serotypes 
Iceland 45 42 0  2 6B (1), 14 (1) 
N. Canada 31 31 0  0  
U.S. Arctic 76 69 0  7 6A (1), 6B (2), 9N (1), 14 (2), 19F (1)  
*S=Sensitive, I=Intermediate resistance, R=Fully resistant 
 
Antimicrobial testing was also done for ceftriaxone, ofloxacin/levoflox, chloramphenicol, 
vancomycin, clindamycin, and rifampin.  In the U.S. Arctic three isolates out of 76 tested (4%) 
showed intermediate resistance to chloramphenicol; all isolates tested in Greenland and Iceland 
were sensitive to chloramphenicol.  All isolates tested in N. Canada and the U.S. Arctic were 
sensitive to ceftriaxone, ofloxacin/levoflox, vancomycin, clindamycin, and rifampin.   
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Quality Control 
 
In 2002, three QC panels of seven Streptococcus pneumoniae isolates each were shipped and 
tested by all three reference laboratories.  Serotyping correlation for all 21 isolates was 100.  
Overall correlation of the MIC results within +/- one log2 dilution was 98.1%.  MIC 
discrepancies between laboratories could be explained by differing ranges of antibiotic 
concentrations for each drug tested or incubation methods. 
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 Haemophilus influenzae 
 
Case Demographics
 
Greenland, N. Canada, and the U.S. Arctic reported the occurrence of Haemophilus influenzae in 
each country during 2002.  Greenland reported no cases and therefore will not be included in the 
results.  A total of 19 cases of invasive disease caused by Haemophilus influenzae were reported 
to ICS during 2002 by N. Canada and the U.S. Arctic.  The rate of disease was higher in N. 
Canada (6 per 100,000) than it was in the U.S. Arctic (2 per 100,000).  Median age of cases was 
higher in the U.S. Arctic (39 years) than in N. Canada (1 year).   
 
Haemophilus influenzae Case Demographics, ICS 2002 Data 
Country Population 
# 
Cases 
Sex  
Rate* M (%) 
Median Age 
(range) yrs 
Deaths 
n (CFR†) 
N. Canada 127,721 8 6 4 (57)‡ 1 (<1-14) 0 (0)a
U.S. Arctic 643,786 11 2 5 (45) 39 (<1-74) 1 (9) 
Total 771,507 19 2.5 9 (50) 2 (<1-74) 1 (6) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Sex unknown in (1) case from N. Canada 
aCase outcomes unknown in cases from N. Canada (2) 
 
When stratified by age, the highest rates of disease for both N. Canada and the U.S. Arctic were 
in the <2 years age category where no cases were reported.   
 
Haemophilus influenzae by Age Category, ICS 2002 Data 
Age  N. Canada U.S. Arctic 
Population 4,736 20,625 
Cases (%) 6 (75) 3 (27) <2 yrs 
Rate* 126 15 
Population 43,822 194,454 
Cases (%) 2 (25) 1 (9) 2-19 yrs 
Rate* 5 0.5 
Population 73,764 390,104 
Cases (%) 0 (0) 4 (36) 20-64 yrs 
Rate* 0 1 
Population 5,399 38,603 
Cases (%) 0 (0) 3 (27) 65+ yrs 
Rate* 0 8 
Population 127,721 643,786 
Cases 8 11 All ages  
Rate* 6 2 
*Number of cases per 100,000 per year 
 
Race
 
Race and ethnicity data was reported in 7 of 8 Haemophilus influenzae cases from N. Canada.  
Rates of disease were highest (139 per 100,000) in Aboriginal cases less than two years of age.  
In the U.S. Arctic, overall rates of disease were five times higher in Native populations (5 per 
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100,000) than in non-Native populations (1 per 100,000); the highest rates of disease (56 per 
100,000) occurred in Native children <2 years of age. 
 
Haemophilus influenzae by Race and Age Categories, ICS 2002 Data 
N Canada* US Arctic Age 
(yrs) 
 
Aboriginal Non-Aboriginal Native Non-Native 
Population 3,593 1,143 5,356 15,269 <2 Cases (rate†) 5 (139) 0 (0) 3 (56) 0 (0) 
Population 31,801 12,021 49,057 145,397 2-19 Cases (rate†) 1 (3) 1 (8) 0 (0) 1 (0.7) 
Population 37,331 36,433 63,373 326,731 20-64 Cases (rate†) 0 (0) 0 (0) 3 (5) 1 (0.3) 
Population 3,032 2,367 7,017 31,586 65+ Cases (rate†) 0 (0) 0 (0) 0 (0) 3 (9) 
Population 75,757 51,964 124,803 518,983 All 
Ages Cases (rate†) 6 (8) 1 (2) 6 (5) 5 (1) 
*Race unknown in 1 case <2 years 
†Number of cases per 100,000 per year 
 
Clinical Presentation
 
In N. Canada, the most common clinical presentation associated with Haemophilus influenzae 
was meningitis (50% of reported cases).  The most common clinical presentation in the U.S. 
Arctic was pneumonia (36% of reported cases), followed by septicemia (27%).  
 
Clinical Presentation of Reported Haemophilus influenzae Cases, ICS 2002 Data 
N. Canada U.S. Arctic  
n (%) n (%) 
Pneumonia* 1 (12.5) 4 (36) 
Septicemia 1 (12.5) 3 (27) 
Bacteremia 1 (12.5) 0 (0) 
Meningitis 4 (50) 2 (18) 
Peritonitis 0 (0) 1 (9) 
Pericarditis 0 (0) 1 (9) 
Septic arthritis 1 (12.5) 0 (0) 
Total 8 11 
*with bacteremia 
 
Risk Factors
 
Fifty-seven percent of adult (≥ 18 years) cases of Haemophilus influenzae reported in the U.S. 
Arctic indicated chronic lung disease as an associated risk factor, cigarette smoking was 
indicated in 43% of cases, diabetes in 18%, and immunosuppressive treatment and alcohol abuse 
in 14%.  All reported Haemophilus influenzae cases in N. Canada occurred in children less than 
18 years old. 
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Vaccination Status
 
The Haemophilus influenzae type b (Hib) conjugate vaccine is required as part of routine 
childhood vaccination in N. Canada and the U.S. Arctic.  Two cases of Hib were reported in N. 
Canada and one in the U.S. Arctic.  One case in N. Canada had not received Hib conjugate 
vaccine and, in the second case, vaccine status was unknown.  The one Hib case in the U.S. 
Arctic had received 2 doses of Hib vaccine. 
 
Haemophilus influenzae Case Vaccination Status for Hib Vaccine, ICS 2002 Data 
N. 
Canada 
U.S. 
Arctic 
 
Total cases eligible for Hib vaccine* 7 4 
Vaccine status known in cases eligible for Hib vaccine 5 4 
Cases eligible for Hib vaccine vaccinated (%)† 4 (80) 3 (75) 
*Children less than 5 years of age 
†Percent of vaccine status known cases 
 
Serotypes
 
Haemophilus influenzae Serotypes by Country, ICS 2002 Data 
Serotype N. Canada U.S. Arctic 
n (%) n (%) 
A 4 (57) 4 (36) 
B 2 (29) 1 (9) 
Non-typable 1 (14) 6 (55) 
Total 7 11 
*Of 8 Hi cases in N. Canada, 7 were serotyped 
 
The most common Haemophilus influenzae serotype in N. Canada and the U.S. Arctic was type 
A, 57% and 36% of reported cases, respectively.  The age range of the serotype A cases in N. 
Canada was 0.6-1.4 years and, in the U.S. Arctic, it was 0.5-74 years.  
 
Outcome
 
One death associated with Haemophilus influenzae was reported to ICS in 2002 from the U.S. 
Arctic; there were no deaths in 6 of eight cases in N. Canada for which outcome was reported.  
The overall case fatality ratio for the U.S. Arctic was 9%.  The death occurred in a 60 year old 
non-Native male and the isolate from the case was serotyped as an A.
18 
 Neisseria meningitidis 
 
Case Demographics
 
Greenland, N. Canada and the U.S. Arctic each reported the occurrence of Neisseria meningitidis 
during 2002.  A total of 9 cases of invasive disease caused by Neisseria meningitidis were 
reported to ICS.  The rate of disease was highest in Greenland (4 per 100,000) and similar in N. 
Canada (1 per 100,000) and the U.S. Arctic (1 per 100,000).  One death associated with 
Neisseria meningitidis was reported in the U.S. Arctic. 
 
Neisseria meningitidis Case Demographics, ICS 2002 Data 
Country Population 
# 
Cases 
Sex  
Rate* M (%) 
Median Age 
(range) yrs 
Deaths 
n (CFR†) 
Greenland 56,542 2 4 1 (50) 1.5‡ 0 (0) 
N. Canada 127,721 1 1 0 (0) 2 0 (0) 
U.S. Arctic 643,786 6 1 1 (16) 12 (3-53) 1 (17) 
Total 828,049 9 1 2 (22)  6 (1.5-53) 0 (0) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Age unknown in one Greenland case 
 
When stratified by age, the highest rates of disease occurred in cases less than two years of age 
in Greenland (59 per 100,000) and N. Canada (21 per 100,000), however, this represents only 
one case in each country.  There were no cases in the U.S. Arctic in this age category.  The 
highest rates of disease in the U.S. Arctic occurred in the 2-19 years age category (4 cases, 2 per 
100,000).   
 
Race
 
Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  The single case 
reported in N. Canada occurred in an aboriginal child less than two years of age.  In the U.S. 
Arctic, overall rates of disease were higher in the Native population (2 per 100,000) than non-
Native (1 per 100,000). 
 
Clinical Presentation
 
All Neisseria meningitidis cases in Greenland and N. Canada and 5 of 6 cases in the U.S. Arctic 
presented clinically as meningitis; the remaining U.S. Arctic case presented with septicemia.   
 
Risk Factors
 
Neither Greenland nor Canada reported any risk factors or other medical conditions associated 
with cases of Neisseria meningitidis.  In the U.S. Arctic, smoking, chronic lung disease and 
alcohol abuse were each reported in association with one adult (≥ 18 years) case.  
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 Group A streptococcus 
 
Case Demographics
 
Greenland, N. Canada, and the U.S. Arctic each reported the occurrence of group A 
streptococcus during 2002.  Greenland reported no cases and therefore will not be included in the 
results.  A total of 47 cases of invasive disease caused by group A streptococcus were reported to 
ICS.  The rate of disease was highest in the U.S. Arctic (7 per 100,000) compared to N. Canada 
(4 per 100,000).  Five deaths were associated with group A streptococcus, all in the U.S. Arctic. 
 
Group A streptococcus Case Demographics, ICS 2002 Data 
Country Population 
# 
Cases 
Sex 
Rate* M (%) 
Median Age 
(range) yrs 
Deaths 
n (CFR†) 
N. Canada 127,721 5 4 4 (80) 36 (<1-76) 0 (0) 
U.S. Arctic 643,786 42 7 20 (48) 41 (<1-82) 5 (12) 
Total 818,042 47 6 24 (51) 41 (<1-82) 5 (11) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
 
When stratified by age, the highest rates of disease occurred in 65+ years of age in N. Canada 
(37 per 100,000) and the U.S. Arctic (18 per 100,000).  High rates of disease also occurred in 
cases <2 years of age in both countries.  
 
Group A streptococcus by Age Category, ICS 2002 Data 
Age  N. Canada U.S. Arctic 
Population 4,736 20,625 
Cases (%) 1 (20) 2 (5) <2 yrs 
Rate* 21 10 
Population 43,822 194,454 
Cases (%) 0 (0) 10 (24) 2-19 yrs 
Rate* 0 5 
Population 73,764 390,104 
Cases (%) 2 (40) 23 (55) 20-64 yrs 
Rate* 3 6 
Population 5,399 38,603 
Cases (%) 2 (40) 7 (17) 65+ yrs 
Rate* 37 18 
Population 127,721 643,786 
Total Cases 5 42 All ages  
Rate* 4 7 
*Number of cases per 100,000 per year 
 
Race
 
Race and ethnicity data were collected by N. Canada and the U.S. Arctic.  Rates of disease were 
higher in the Aboriginal and Native populations than in the non-Aboriginal and non-Native 
populations.  All of N. Canada’s group A streptococcus disease occurred in Aboriginals. 
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Group A streptococcus by Race and Age Categories, ICS 2002 Data 
N. Canada* U.S. Arctic* Age 
(yrs) 
 
Aboriginal Non-Aboriginal Native Non-Native 
Population 3,593 1,142 5,356 15,269 <2 Cases (rate†) 1 (28) 0 (0) 2 (37) 0 (0) 
Population 31,801 12,021 49,057 145,397 2-19 Cases (rate†) 0 (0) 0 (0) 9 (18) 1 (1) 
Population 37,331 36,433 63,373 326,731 20-64 Cases (rate†) 1 (3) 0 (0) 8 (13) 15 (5) 
Population 3,032 2,367 7,017 31,586 65+ Cases (rate†) 2 (66) 0 (0) 1 (14) 5 (16) 
Population 75,757 51,964 124,803 518,983 All 
Ages Cases (rate†) 4 (5) 0 (0) 20 (16) 21 (4) 
*Race unknown in 1 N. Canada case 20-64 years, 1 U.S. Arctic cases 65+ years 
†Number of cases per 100,000 per year 
 
Clinical Presentation
 
In the U.S. Arctic, 45% of group A streptococcus cases presented clinically with cellulitis, 17% 
presented with septicemia.  Two of the cases (40%) in N. Canada presented with septicemia and 
two (40%) with cellulitis.   
 
Clinical Presentation of Reported group A streptococcus Cases, ICS 2002 Data 
N. Canada U.S. Arctic  
n (%) n (%) 
Pneumonia* 0 (0) 4 (9) 
Bacteremia 0 (0) 3 (7) 
Septicemia 2 (40) 7 (17) 
Meningitis 0 (0) 1 (2) 
Empyema 0 (0) 1 (2) 
Cellulitis* 2 (40) 19 (45) 
Necrotizing fasciitis 0 (0) 4 (9) 
Peritonitis 0 (0) 1 (2) 
Septic arthritis 0 (0) 1 (2) 
Osteomyelitis 0 (0) 1 (2) 
Other 1 (20) 0 (0) 
Total 5 42 
*with bacteremia 
 
Risk Factors
 
N. Canada reported diabetes associated with one adult (≥ 18 years) case of group A 
streptococcus in 2002.  In the U.S. Arctic, cigarette smoking was reported in 26% of adult cases, 
chronic lung disease in 16%, alcohol abuse in 23%, and diabetes was reported in 16%.  Immune 
suppressive treatment was reported in 3 U.S. Arctic adult cases and injection drug use in one 
adult case. 
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Outcome
 
Five deaths in cases with group A streptococcus were reported from the U.S. Arctic (CFR 12%); 
one death occurred in each of the 2-19 and 20-64 year old age categories and three deaths 
occurred in the 65+ year old age category.  No deaths were reported in N. Canada.   
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 Group B streptococcus 
 
Case Demographics
 
Greenland, N. Canada, and the U.S. Arctic each reported the occurrence of group B 
streptococcus during 2002.  Greenland reported no cases and therefore will not be included in the 
results.  A total of 25 cases of invasive disease caused by group B streptococcus were reported to 
ICS.  The rate of disease was highest in the U.S. Arctic (4 per 100,000) compared to N. Canada 
(2 per 100,000).  Five deaths were reported in the U.S. Arctic associated with group B 
streptococcus in 2002. 
 
Group B streptococcus Case Demographics, ICS 2002 Data 
Country Population 
# 
Cases 
Sex 
Rate* M (%) 
Median Age 
(range) yrs 
Deaths 
n (CFR†) 
N. Canada 127,721 2 2 0 (0) 14 (<1-28) 0 (0) 
U.S. Arctic 643,786 23 4 12 (52) 46 (<1-75) 5 (22) 
Total 818,042 25 3 12 (48) 43 (<1-75) 5 (20) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
 
When stratified by age, the highest rates of disease occurred in cases less than two years of age 
in N. Canada (21 per 100,000) and the U.S. Arctic (39 per 100,000).   
 
Group B streptococcus by Age Category, ICS 2002 Data 
Age  N. Canada U.S. Arctic 
Population 4,736 20,625 
Cases (%) 1 (50) 8 (35) <2 yrs 
Rate* 21 39 
Population 43,822 194,454 
Cases (%) 0 (0) 0 (0) 2-19 yrs 
Rate* 0 0 
Population 73,764 390,104 
Cases (%) 1 (50) 10 (43) 20-64 yrs 
Rate* 1 3 
Population 5,399 38,603 
Cases (%) 0 (0) 5 (22) 65+ yrs 
Rate* 0 13 
Population 127,721 643,786 
Total Cases 2 23 All ages  
Rate* 2 4 
*Number of cases per 100,000 per year 
 
Four of the cases that occurred in the less than 2 years age category in the U.S. Arctic were early 
onset (less than 7 days old) and three cases were late onset (7 to 90 days) for rates of 
40.4/100,000 and 30.3/100,000, respectively. 
 
23 
 
Race
 
Race and ethnicity data was collected in N. Canada and the U.S. Arctic.  All invasive disease 
caused by group B streptococcus in N. Canada occurred in Aboriginals.  The highest rates of 
disease occurred in N. Canada Aboriginal and Alaska non-Native cases less than two years of 
age, 28 and 46 per 100,000 respectively. 
 
Group B streptococcus by Race and Age Categories, ICS 2002 Data 
N. Canada U.S. Arctic Age 
(yrs) 
 
Aboriginal Non-Aboriginal Native Non-Native 
Population 3,593 1,142 5,356 15,269 <2 Cases (rate*) 1 (28) 0 (0) 1 (19) 7 (46) 
Population 31,801 12,021 49,057 145,397 2-19 Cases (rate*) 0 (0) 0 (0) 0 (0) 0 (0) 
Population 37,331 36,433 63,373 326,731 20-64 Cases (rate*) 1 (3) 0 (0) 3 (5) 7 (2) 
Population 3,032 2,367 7,017 31,586 65+ Cases (rate*) 0 (0) 0 (0) 1 (14) 4 (13) 
Population 75,757 51,964 124,803 518,983 All 
Ages Cases (rate*) 2 (3) 0 (0) 5 (4) 18 (4) 
*Number of cases per 100,000 per year 
 
Clinical Presentation
 
In the U.S. Arctic, cellulitis was the most common clinical presentation (26%) reported for cases 
of group B streptococcus in 2002.  One case in N. Canada presented with septicemia and one 
with cellulitis. 
 
Clinical Presentation of Reported group B streptococcus Cases, ICS 2002 Data 
N. Canada U.S. Arctic  
n (%) n (%) 
Pneumonia* 0 (0) 3 (13) 
Septicemia 1 (50) 5 (22) 
Meningitis 0 (0) 5 (22) 
Peritonitis 0 (0) 2 (9) 
Cellulitis* 1 (50) 6 (26) 
Endocarditis 0 (0) 1 (4) 
Other 0 (0) 1 (4) 
Total 2 23 
*with bacteremia 
 
Risk Factors
 
N. Canada reported smoking, alcohol abuse and immune suppressive treatment associated risk 
factors or medical conditions with the one adult (≥ 18 years) case of group B streptococcus in 
2002.  In the U.S. Arctic, diabetes was reported in 67% of adult cases, alcohol abuse in 27%, 
cigarette smoking in 20%, and chronic lung disease in 13%. 
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Outcome
 
Five deaths in cases with group B streptococcus were reported in the U.S. Arctic (CFR 22%); 
two deaths occurred each in the <2 and 20-64 age categories and one in the 65+ age category.  
No deaths were reported in N. Canada.   
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CONCLUSIONS 
 
The ICS program continued to expand in 2002.  In addition to collecting Streptococcus 
pneumoniae data from six Arctic countries, Greenland has joined N. Canada and the U.S. Arctic 
in reporting invasive bacterial disease caused by Hi, Nm, GAS and GBS.  Monitoring rates of 
disease and levels of antimicrobial resistance in these pathogens via use of the ICS system is 
important, and efforts to expand ICS to include all circumpolar nations will continue. 
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Länsi-Pohjan keskussairaalan laboratorio 
Mikkelin keskussairaalan mikrobiologian laboratorio 
OYKS – Mikrobiologian laboratorio 
Oulun kiakonissalairoksen laboratorio 
Pohjois-Karjalan keskussairaalan mikrobiologian laboratorio 
Päijät-Hämeen keskussairaalan mikrobiologian laboratorio 
Rauman aluesairaalan laboratorio 
Satakunnan keskussairaalan mikrobiologian laboratorio 
Savonlinnan keskussairaalan laboratorio 
TAYS – Mikrobiologian laboratorio 
TYKS – Mikrobiologian laboratorio 
Vaasan keskussairaalan mikrobiologian laboratorio 
 
GREENLAND 
Reference 
Laboratories 
Statens Serum Institute, Copenhagen, Denmark 
Centralab at Queen Ingrid’s Hospital, Nuuk, Greenland 
Laboratories Nanortalik Hospital 
Qaqortoq Hospital 
Narsaq Hospital 
Paamiut Hospital 
Maniitsoq Hospital 
Sisimut Hospital 
Aasiaat Hospital 
Qasigiannguit Hospital 
Ilulissat Hospital 
Qeqertarsuaq Hospital 
Uummannaq Hospital 
Upernavik Hospital 
Qaanaaq Hospital 
Ammassalik Hospital 
Ittoqqortoormiit Hospital 
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ICELAND 
Reference 
Laboratory 
Department of Microbiology, Landspitali University Hospital, 
Reykjavik 
Laboratories Akranes Hospital 
Isafjordur District Hospital 
Stykkisholmur Local Health Center 
St. Joseph’s Hospital Hafnarfjorour 
Municipal Hospital of Vestmannaeyjar 
Akureyri 
Egilstadir Health Center 
Selfoss Health Center 
Sudurnes Health Center (Keflavik) 
Regional Hospital Neskaupstadur 
 
NORTHERN CANADA 
Laboratory Centre 
for Disease Control 
Respiratory Division, Bureau of Infectious Diseases, Laboratory 
Centre for Disease Control, Ottawa 
Reference 
Laboratories 
National Centre for Streptococcus, Provincial Laboratory of Public 
Health, Edmonton, AB 
Laboratoire de Santé Publique du Québec, Montréal, QC 
National Centre for Meningococcus, Provincial Laboratory of Public 
Health, Winnipeg, MB 
Laboratories Whitehorse General Hospital, Whitehorse, YK 
Stanton Regional Health Board, Yellowknife, NT 
H.H. Williams Memorial Hospital, Hay River, NT 
Inuvik Regional Hospital, Inuvik, NT 
Baffin Regional Hospital, Iqaluit, NU 
Churchill Regional Health Authority, Churchill, MB 
Cadham Provincial Laboratory, Winnipeg, MB 
Ungava Tulattavik Health Centre, Kuujjuaq, QC 
Inulitsavik Hospital, Puvirnituq, QC 
Cree Health Board, Chisasibi, QC 
CSSSR, Chibougamou, QC 
Val d’Or Hospital, Val d’Or, QC 
Melville Hospital, Goose Bay, NL 
Newfoundland Public Health Laboratory, St. John’s, NL 
Public Health Yukon Communicable Disease Control, Whitehorse, YK 
Health Protection Unit, Government of NWT, Yellowknife, NT 
JA Hildes Northern Medical Unit, Winnipeg, MB 
Régie Régionale de la Santé et des Services Sociaux, Kuujjuaq, QC 
Région Cri de la Baie James, Module de Santé Publique, Montreal, 
QC 
Communicable Disease Control, Health Laborador Corporation, 
Goose Bay, NL 
IMPAct Coordinator, Vaccine Evaluation Centre, Vancouver, BC 
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NORWAY 
Reference 
Laboratory 
Oslo/Tromso 
Laboratories Frederikstad, Østf. SSH 
Sarpsborg SH 
Akershus SSH, SiA 
Bœrum SH 
Aker SH 
Fürsts laborat, Oslo 
Dr. Willes med.lab. 
Radiumhospitalet 
Folkehelsa, vir.lab. 
Folkehelsa, bakt.lab. 
Forsv.mik.lab.Folk.h. 
Rikshospitalet, mik.lab. 
Ullevål SH, mik.lab. 
Lab. klin. mikrob. Oslo 
Lillehammer mik.lab 
Elverum mik.lab. 
Buskerud SSH, mik.lab. 
Vestfold SSH, mik.lab. 
Telelab 
Vest-Agder SSH, mik.lab. 
Rogaland SSH, mik.lab. 
Haukeland SH, mik.lab. 
Sogn-Fk. SSH, mik.lab. 
Ålesund FSH, mik.lab. 
Molde FSH, mik.lab. 
Trondheim RSH, mik.lab. 
Innherred SH, mik.lab. 
Namdal SH, mik.lab. 
Nordland SSH, mik.lab. 
Tromsø RSH, mik.lab. 
Kirkenes SH, mik.lab. 
Laboratorium INA/div. 
Haugesund, mik.lab. 
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U.S. ARCTIC 
Reference 
Laboratory 
Arctic Investigations Program, National Center for Infectious 
Diseases, Centers for Disease Control and Prevention, Anchorage, AK 
Laboratories Alaska Native Medical Center, Anchorage, AK 
Alaska Regional Hospital, Anchorage, AK 
Bartlett Regional Hospital, Juneau, AK 
Bassett Army Hospital, Fort Wainwright, AK 
Central Peninsula General Hospital, Soldotna, AK 
Cordova Community Medical Center, Cordova, AK 
Elmendorf Air Force Base Hospital, Anchorage, AK 
Fairbanks Memorial Hospital, Fairbanks, AK 
Kanakanak Hospital, Dillingham, AK 
Ketchikan Regional Hospital, Ketchikan, AK 
Manilaq Medical Center, Kotzebue, AK 
Norton Sound Regional Hospital, Nome, AK 
Petersburg Medical Center, Petersburg, AK 
Providence Alaska Medical Center, Anchorage, AK 
Providence Island Medical Center, Kodiak, AK 
Samuel Simmonds Memorial Hospital, Barrow, AK 
Sitka Community Hospital, Sitka, AK 
South Peninsula Hospital, Homer, AK 
Southeast Area Regional Health Corporation, Sitka, AK 
State Public Health Laboratory, Division of Public Health, 
Department of Health and Social Services, Anchorage, AK 
Valdez Community Hospital, Valdez, AK 
Valley Hospital, Palmer, AK 
Wrangell General Hospital, Wrangell, AK 
Yukon-Kuskokwim Delta Regional Hospital, Bethel, AK 
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